Galectin-3-targeted antifungal prophylaxis in influenza patients in intensive care
The GALActIC project is a novel international research initiative focusing on the improvement of the early detection and treatment of Influenza-Associated Pulmonary Aspergillosis (IAPA)—a severe fungal infection with a mortality rate of up to 50%. By identifying genetic biomarkers in the LGALS3 gene, we want to enable personalized antifungal prophylaxis and ensure that high-risk patients receive timely and targeted treatment.
Led by an international team of four partners:
- Belgium (UZ Leuven)
- Austria (Med Uni Graz | Translationale medizinische Mykologie)
- The Netherlands (Welcome to Radboudumc Community for Infectious Diseases – Radboudumc)
- Portugal (Immunobiology of Inflammatory and Infectious Diseases – ICVS) and
- France (Centre for Biomedical and Healthcare Engineering – MINES Saint-Étienne),
GALActIC combines genetic research, multi-omics analysis, and clinical data to improve the management of IAPA. Our mission: reduce mortality, enhance patient outcomes, and optimize healthcare resources with the help of precision medicine.
